These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 23257920)

  • 1. Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice.
    Potthoff MJ; Potts A; He T; Duarte JA; Taussig R; Mangelsdorf DJ; Kliewer SA; Burgess SC
    Am J Physiol Gastrointest Liver Physiol; 2013 Feb; 304(4):G371-80. PubMed ID: 23257920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism.
    Pathak P; Liu H; Boehme S; Xie C; Krausz KW; Gonzalez F; Chiang JYL
    J Biol Chem; 2017 Jun; 292(26):11055-11069. PubMed ID: 28478385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study.
    Beysen C; Murphy EJ; Deines K; Chan M; Tsang E; Glass A; Turner SM; Protasio J; Riiff T; Hellerstein MK
    Diabetologia; 2012 Feb; 55(2):432-42. PubMed ID: 22134839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells.
    Trabelsi MS; Daoudi M; Prawitt J; Ducastel S; Touche V; Sayin SI; Perino A; Brighton CA; Sebti Y; Kluza J; Briand O; Dehondt H; Vallez E; Dorchies E; Baud G; Spinelli V; Hennuyer N; Caron S; Bantubungi K; Caiazzo R; Reimann F; Marchetti P; Lefebvre P; Bäckhed F; Gribble FM; Schoonjans K; Pattou F; Tailleux A; Staels B; Lestavel S
    Nat Commun; 2015 Jul; 6():7629. PubMed ID: 26134028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1.
    Shang Q; Saumoy M; Holst JJ; Salen G; Xu G
    Am J Physiol Gastrointest Liver Physiol; 2010 Mar; 298(3):G419-24. PubMed ID: 20044510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism.
    Pathak P; Xie C; Nichols RG; Ferrell JM; Boehme S; Krausz KW; Patterson AD; Gonzalez FJ; Chiang JYL
    Hepatology; 2018 Oct; 68(4):1574-1588. PubMed ID: 29486523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Bile Acids and GLP-1 in Mediating the Metabolic Improvements of Bariatric Surgery.
    Albaugh VL; Banan B; Antoun J; Xiong Y; Guo Y; Ping J; Alikhan M; Clements BA; Abumrad NN; Flynn CR
    Gastroenterology; 2019 Mar; 156(4):1041-1051.e4. PubMed ID: 30445014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bile acid sequestrants in type 2 diabetes: potential effects on GLP1 secretion.
    Sonne DP; Hansen M; Knop FK
    Eur J Endocrinol; 2014 Aug; 171(2):R47-65. PubMed ID: 24760535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between bile acid concentration, glucagon-like-peptide 1, fibroblast growth factor 15 and bile acid receptors in rats during progression of glucose intolerance.
    Yan X; Li P; Tang Z; Feng B
    BMC Endocr Disord; 2017 Sep; 17(1):60. PubMed ID: 28946907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion.
    Hansen M; Scheltema MJ; Sonne DP; Hansen JS; Sperling M; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
    Diabetes Obes Metab; 2016 Jun; 18(6):571-80. PubMed ID: 26888164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond intestinal soap--bile acids in metabolic control.
    Kuipers F; Bloks VW; Groen AK
    Nat Rev Endocrinol; 2014 Aug; 10(8):488-98. PubMed ID: 24821328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptor- and liver X receptor alpha-controlled metabolic pathways in mice.
    Herrema H; Meissner M; van Dijk TH; Brufau G; Boverhof R; Oosterveer MH; Reijngoud DJ; Müller M; Stellaard F; Groen AK; Kuipers F
    Hepatology; 2010 Mar; 51(3):806-16. PubMed ID: 19998408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Takeda G Protein-Coupled Receptor 5-Mechanistic Target of Rapamycin Complex 1 Signaling Contributes to the Increment of Glucagon-Like Peptide-1 Production after Roux-en-Y Gastric Bypass.
    Zhai H; Li Z; Peng M; Huang Z; Qin T; Chen L; Li H; Zhang H; Zhang W; Xu G
    EBioMedicine; 2018 Jun; 32():201-214. PubMed ID: 29859856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of Transmembrane Bile Acid Receptor TGR5 Modulates Pancreatic Islet α Cells to Promote Glucose Homeostasis.
    Kumar DP; Asgharpour A; Mirshahi F; Park SH; Liu S; Imai Y; Nadler JL; Grider JR; Murthy KS; Sanyal AJ
    J Biol Chem; 2016 Mar; 291(13):6626-40. PubMed ID: 26757816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GLP-2 receptor signaling controls circulating bile acid levels but not glucose homeostasis in Gcgr
    Patel A; Yusta B; Matthews D; Charron MJ; Seeley RJ; Drucker DJ
    Mol Metab; 2018 Oct; 16():45-54. PubMed ID: 29937214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-like peptide-2 promotes gallbladder refilling via a TGR5-independent, GLP-2R-dependent pathway.
    Yusta B; Matthews D; Flock GB; Ussher JR; Lavoie B; Mawe GM; Drucker DJ
    Mol Metab; 2017 Jun; 6(6):503-511. PubMed ID: 28580281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colesevelam attenuates cholestatic liver and bile duct injury in
    Fuchs CD; Paumgartner G; Mlitz V; Kunczer V; Halilbasic E; Leditznig N; Wahlström A; Ståhlman M; Thüringer A; Kashofer K; Stojakovic T; Marschall HU; Trauner M
    Gut; 2018 Sep; 67(9):1683-1691. PubMed ID: 29636383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist.
    Rizzo G; Passeri D; De Franco F; Ciaccioli G; Donadio L; Rizzo G; Orlandi S; Sadeghpour B; Wang XX; Jiang T; Levi M; Pruzanski M; Adorini L
    Mol Pharmacol; 2010 Oct; 78(4):617-30. PubMed ID: 20631053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TGR5 potentiates GLP-1 secretion in response to anionic exchange resins.
    Harach T; Pols TW; Nomura M; Maida A; Watanabe M; Auwerx J; Schoonjans K
    Sci Rep; 2012; 2():430. PubMed ID: 22666533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bile acid treatment and FXR agonism lower postprandial lipemia in mice.
    Farr S; Stankovic B; Hoffman S; Masoudpoor H; Baker C; Taher J; Dean AE; Anakk S; Adeli K
    Am J Physiol Gastrointest Liver Physiol; 2020 Apr; 318(4):G682-G693. PubMed ID: 32003602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.